Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Debt to Equity (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Debt to Equity for 3 consecutive years, with $0.02 as the latest value for Q4 2025.

  • Quarterly Debt to Equity changed N/A to $0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.02 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.02 for FY2025, N/A changed from the prior year.
  • Debt to Equity for Q4 2025 was $0.02 at Century Therapeutics, down from $0.05 in the prior quarter.
  • The five-year high for Debt to Equity was $0.05 in Q3 2025, with the low at $0.02 in Q4 2025.
  • Average Debt to Equity over 3 years is $0.03, with a median of $0.03 recorded in 2022.
  • Peak annual rise in Debt to Equity hit 43.39% in 2023, while the deepest fall reached 43.39% in 2023.
  • Over 3 years, Debt to Equity stood at $0.03 in 2022, then increased by 9.82% to $0.04 in 2023, then plummeted by 36.37% to $0.02 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.02, $0.05, and $0.04 for Q4 2025, Q3 2025, and Q1 2023 respectively.